This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytokinetics' CEO Discusses Q2 2012 Results - Earnings Call Transcript

I'll then provide a financial overview and comments with respect to our cash position, details on our investments in research and development activities, as well as updated financial guidance for 2012.

Robert will then conclude the call with additional comments regarding recent activities and expected next steps for our development stage programs as well as an update regarding projected company milestones for the remainder of 2012. We will then open the call for a brief question and answer session.

The following discussion including our responses to questions contain statements that constitute forward-looking statements for the purposes of the Safe Harbor provisions of the private securities litigation reform act of 1995. Including but not limited to statements relating to our financial guidance, to the initiation enrollment designed conduct and results of clinical trials, and to other research and development activities.

Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those forward-looking statements is contained in our SEC filings including our most recent annual report on form 10-K, our quarterly reports on form 10-Q, and our current reports on form AK. Copies of these documents may be obtained from the SEC or by visiting the investor relations section of our website. These forward-looking statements speak only as of today. You should not rely on them as representing our views in the future. And we undertake no obligation to update these statements after this call.

Now I'll turn the call over to Robert.

Robert Blum

Thank you, Sharon.

During the second quarter, we took important steps to insure that we continue to build on the progress reported in the first quarter. And remain focused to key value driving milestones.

In recent months, we have received notifications of each of the United States adopted names or USA End Council and the World Health Organizations Consultation on International Non-Proprietary Names for pharmaceutical substances program that indicated the adoption of tirasemtiv as the generic name for CK-2017357. Going forward and on this call today, we will use the newly adopted generic name tirasemtiv when referring to the lead development compound in our skeletal muscle activator program directed to the potential treatment of Amyotrophic lateral sclerosis or ALS.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.58 -0.71%
FB $118.08 0.23%
GOOG $705.18 0.53%
TSLA $209.56 -0.93%
YHOO $36.81 -0.35%


Chart of I:DJI
DOW 17,590.58 -70.13 -0.40%
S&P 500 2,042.16 -8.47 -0.41%
NASDAQ 4,689.8610 -27.2330 -0.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs